Tag: David W. Goodman MD

01

Jan2017
Surman C, Goodman DW. ADHD Atten Def Hyp Disord. Jan2017. click to read abstract
January 1, 2017RoseMarie AddAdult

17

Nov2016
Young J, Goodman DW. Primary Care Companion CNS Disord. 2016,18(6) click to read abstract
November 17, 2016RoseMarie AddAdult

05

Sep2016
Goodman DW, Adler LA. Medscape, September 2016. CME accredited
September 5, 2016RoseMarie AddAdult

11

Aug2016
I was invited to assist with background information on ADHD in women and offered my insights on the gender differences when dealing with ADHD. I invite you to read the article and celebrate the increased attention to the gender differences of ADHD. ADHD in women is now an ongoing topic of ... Read More
August 11, 2016David W. Goodman, MD

04

Jul2016
Despite decades of articles on the science and research of ADHD, it never ceases to amaze me when I have a conversation with people who don't believe in ADHD. While I understand concerns of "the label" and "bad medicine", I have seen thousands of patients who, when treated for the ... Read More

12

Mar2016
Since the recent publication of our literature of published research on ADHD in adults over age 50, several news outlets have been interested in bring this subject to the public eye. ADHD in adults persists throughout one’s life. It does not go away because you got your AARP card or ... Read More
March 12, 2016David W. Goodman, MD

27

Jan2016
It appears that the topic of ADHD in older adults is catching some attention. I was invited by Ann Fisher of WOSU Radio (NPR affiliate) in Columbia, Ohio to discuss adult ADHD especially in older adults. The host, Ann, asked insightful questions about identification and diagnosis in older adult and how ... Read More
January 27, 2016David W. Goodman, MD

11

Dec2015
Goodman DW, Mitchell S, Rhodewalt L, Surman CBH. Drugs and Aging. Dec 2015. p1-10. Abstract Although previously considered a disorder of childhood, studies in the last decade have demonstrated that attention-deficit hyperactivity disorder (ADHD) continues to impair function into adulthood and responds to pharmacotherapy. Due to age-specific changes in roles and challenges, ... Read More
December 11, 2015Jourdan Hathaway

11

Dec2015
Vayarin is marketed as a “medical food” for the treatment of ADHD. Vayarin contains Phosphatidylserine 75 mg, Eicosapentaenoic acid (EPA) 21.5 mg, and Docosahexaenoic acid (DHA) 8.5 mg. These ingredients are omega3 fatty acids. The recommended dose is 4 pills daily. The company sponsored a 15-week, double blind, placebo controlled trial ... Read More
December 11, 2015David W. Goodman, MD

04

Nov2015
Insurance companies and "health care coordinators" are increasingly insinuating themselves into the care of patients. While we are all accustom to generic substitutions as a cost saving measure, you may not be aware that a pharmacist of CareFirst is "working with primary care physicians" to review cost effective medication treatments ... Read More
November 4, 2015David W. Goodman, MD